Tottenham Hotspur have been linked with multiple managers in recent weeks, and it appears that the Fulham manager, Marco Silva, is the main target. According to the reliable Italian journalist ...

Bodo/Glimt record scorer Stig Johansen believes Tottenham are in for a shock in their Europa League semi-final second leg. Tottenham hold a 3-1 lead before Thursday's game in north Norway ...

Tottenham midfielder James Maddison insists the team are "100 per cent behind" boss Ange Postecoglou despite their "unacceptable" Premier League season. Spurs sit a lowly 16th in the Premier ...

Kevin Lynch is a London-born, Dublin-based writer and journalist. The author of Steve Jobs: A Biographic Portrait, Kevin is a regular feature writer for a number of tech sites and the former ...

compared to 9% on the road. An all-English final in Bilbao could be on the cards with Manchester United winning their tie 3-0 at Athletic Club. Domestically Tottenham are facing their worst season ...

James Maddison has admitted Tottenham’s league form has been “unacceptable” and warned that talk surrounding Ange Postecoglou’s future is “not healthy”, but insists the squad remains ...

U.S.-listed shares of GSK are gaining in intraday trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the ...

And even though the price has recovered from that dip, it’s still down 11% year to date. GSK reported a 2% revenue rise at actual exchange rates (4% at constant rates), driven largely by a 17% ...

Tottenham are open to selling Manor Solomon this summer and Leeds are growing increasingly confident a deal will soon be agreed following his impressive loan spell at Elland Road and despite rival ...

GSK (NYSE:GSK) reported Q1 2025 results on Wednesday, narrowly beating analysts’ estimates as the British drugmaker’s Specialty Medicines business offset weakness in its Vaccine and General ...

GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago. These figures are ...

Drugmaker GSK has today reaffirmed its outlook for 2025 and said it was "well positioned" to mitigate any hit from potential sector-specific tariffs, after first quarter results beat expectations.